IRIS

trans-1,2-Dichloroethylene

CASRN 156-60-5

IRIS Toxicological Review of Cis-& Trans-1,2-Dichloroethylene (Final Report)

Overview

EPA has finalized the Toxicological Review of cis- & trans-1,2-Dichloroethylene: in support of the Integrated Risk Information System (IRIS). Now final, this assessment may be used by EPA’s program and regional offices to inform decisions to protect human health.

Citation

U.S. EPA. IRIS Toxicological Review of Cis-& Trans-1,2-Dichloroethylene (Final Report). U.S. Environmental Protection Agency, Washington, DC, EPA/635/R-09/006F, 2010.

Top of Page

Background

1,2-Dichloroethylene is used as a solvent for waxes and resins, in rubber extraction, and as a coolant in refrigeration plants. The cis- and trans- isomers have slightly different physical, chemical, and biological properties. The trans-isomer is more widely used. 1,2-Dichloroethylene is frequently detected at federal and state hazardous waste sites across the country.

History/Chronology

Date Description
01-Sep 1988EPA posted the trans-1,2-dichloroethylene (RfD only).
02-Dec 1990EPA posted the cis-1,2-dichloroethylene (qualitative cancer assessment only).
03-Aug 2009EPA hosted an interagency science consultation on the review of the draft IRIS Summary and Toxicological Review of cis-1,2-Dichloroethylene and trans-1,2-Dichloroethylene.
04-Sep 2009EPA released an external review draft of the assessment for public review and comment.
05-Nov 2009EPA announces the external peer review workshop to be held on December 17, 2009. [Federal Register Notice Nov 10, 2009]
06-Jan 2010EPA releases the comments from the external review workshop and public comment period.
07-Jul 2010EPA hosted an interagency science discussion on the review of the draft Toxicological Review of cis- and trans-1,2-dichloroethylene.
09-Sep 2010EPA releases the final report and IRIS Summary and the interagency review draft with comments.


Top of Page

Download(s)

This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

If you have a disability and the format of any material on our web pages interferes with your ability to access the information, please reach out to us using the Contact us about IRIS form for assistance. To enable us to respond in a manner most helpful to you, please indicate the nature of the accessibility problem, the web address of the requested material, your preferred format in which you want to receive the material (electronic format (ASCII, etc.), standard print, large print, etc.), and your contact information.

Top of Page